Literature DB >> 28377612

Dominant TNFα and impaired IL-2 cytokine profiles of CD4+ T cells from children with type-1 diabetes.

Julia Seyfarth1,2, Katharina Förtsch1, Heinz Ahlert1, Hans-Juergen Laws3, Beate Karges4, Rene Deenen5, Karl Köhrer5, Ertan Mayatepek1, Thomas Meissner1,2, Marc Jacobsen1.   

Abstract

Aberrantly activated CD4+ T memory cells play a central role in the development of type-1-diabetes. Interleukin-7 promotes generation of autoimmune memory T cells and increased Interleukin-7 availability is associated with type-1-diabetes susceptibility. T-cell-mediated immune pathology at onset of type-1-diabetes is well defined, but characteristics of long-term symptomatic disease stages remain largely elusive. In the present study, memory CD4+ T-cell activation and cytokine expression as well as sensitivity to Interleukin-7 in vitro were compared between patients with type-1-diabetes at clinical onset (n=25), long-term symptomatic disease (median duration 4.5 years, n=19) and matched healthy controls (n=21). T-cell responses of type-1-diabetes patients were characterized by higher frequencies of cytokine and activation marker expressing CD4+ memory T cells as compared to healthy controls. Notably, correction for individual cytokine expression levels revealed qualitative differences of cytokine profiles characterized by significantly increased TNFα and decreased IL-2-expressing T-cell proportions in long-term type-1-diabetes patients. IL-7-mediated T-cell co-stimulation induced quantitative and qualitative cytokine expression differences highly similar to type-1-diabetes-specific profiles. In addition, CD4+ memory T cells from children with long-term type-1-diabetes were more sensitive to in vitro IL-7 co-stimulation. Global transcriptome analysis revealed IL-7 induced expression differences of CD4+ T cells, including increased IL-2R expression and effects on subsequent T-cell receptor activation. We conclude that long-term symptomatic type-1-diabetes patients differed in memory T-cell cytokine profiles and Interleukin-7 co-stimulation. Regulation of IL-2 expression and sensitivity are affected with possible consequences for disease course and severity at long-term type-1-diabetes stages.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28377612     DOI: 10.1038/icb.2017.24

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  50 in total

Review 1.  The case for an autoimmune aetiology of type 1 diabetes.

Authors:  S I Mannering; V Pathiraja; T W H Kay
Journal:  Clin Exp Immunol       Date:  2015-10-21       Impact factor: 4.330

2.  TNF-α Antibody Therapy in Combination With the T-Cell-Specific Antibody Anti-TCR Reverses the Diabetic Metabolic State in the LEW.1AR1-iddm Rat.

Authors:  Anne Jörns; Ümüs Gül Ertekin; Tanja Arndt; Taivankhuu Terbish; Dirk Wedekind; Sigurd Lenzen
Journal:  Diabetes       Date:  2015-03-17       Impact factor: 9.461

3.  Cytomegalovirus infection- and age-dependent changes in human CD8+ T-cell cytokine expression patterns.

Authors:  Benjamin Faist; Bernhard Fleischer; Marc Jacobsen
Journal:  Clin Vaccine Immunol       Date:  2010-04-28

4.  Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope.

Authors:  Sally C Kent; Yahua Chen; Lisa Bregoli; Sue M Clemmings; Norma Sue Kenyon; Camillo Ricordi; Bernhard J Hering; David A Hafler
Journal:  Nature       Date:  2005-05-12       Impact factor: 49.962

5.  Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation.

Authors:  André Ballesteros-Tato; Beatriz León; Beth A Graf; Amy Moquin; Pamela Scott Adams; Frances E Lund; Troy D Randall
Journal:  Immunity       Date:  2012-03-29       Impact factor: 31.745

6.  Factors Associated with Higher Pro-Inflammatory Tumor Necrosis Factor-α Levels in Young Women with Type 1 Diabetes.

Authors:  K K Danielson; R S Monson; T J LeCaire
Journal:  Exp Clin Endocrinol Diabetes       Date:  2016-03-23       Impact factor: 2.949

Review 7.  CD4 T cell differentiation in type 1 diabetes.

Authors:  L S K Walker; M von Herrath
Journal:  Clin Exp Immunol       Date:  2015-07-28       Impact factor: 4.330

8.  Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.

Authors:  S Alice Long; Karen Cerosaletti; Paul L Bollyky; Megan Tatum; Heather Shilling; Sheng Zhang; Zhong-Yin Zhang; Catherine Pihoker; Srinath Sanda; Carla Greenbaum; Jane H Buckner
Journal:  Diabetes       Date:  2009-10-29       Impact factor: 9.461

9.  Follicular helper T cell signature in type 1 diabetes.

Authors:  Rupert Kenefeck; Chun Jing Wang; Tauseef Kapadi; Lukasz Wardzinski; Kesley Attridge; Louise E Clough; Frank Heuts; Alexandros Kogimtzis; Sapna Patel; Miranda Rosenthal; Masahiro Ono; David M Sansom; Parth Narendran; Lucy S K Walker
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

10.  Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement.

Authors:  Agata Kosmaczewska; Jerzy Swierkot; Lidia Ciszak; Aleksandra Szteblich; Agnieszka Chrobak; Lidia Karabon; Anna Partyka; Jacek Szechinski; Piotr Wiland; Irena Frydecka
Journal:  Rheumatol Int       Date:  2013-11-13       Impact factor: 2.631

View more
  1 in total

1.  CD4+ T-Cells With High Common γ Chain Expression and Disturbed Cytokine Production Are Enriched in Children With Type-1 Diabetes.

Authors:  Julia Seyfarth; Nathalie Mütze; Jennifer Antony Cruz; Sebastian Kummer; Christina Reinauer; Ertan Mayatepek; Thomas Meissner; Marc Jacobsen
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.